Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab and MEDI3617 in Unresectable Stage III or IV Melanoma
NCT02141542Phase 1Completed
- Start
- May 2014
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MEDI3617 in melanoma. Primary endpoint: Maximum Tolerated Dose at 2 years. Started May 2014; status: completed.
02
Drugs
MEDI3617
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02141542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02141542.